Small Cell Lung Cancer: A Review

Area of Science:

• Oncology
• Pulmonology
• Medical Oncology

Background:

• Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor, primarily linked to smoking, with a low 5-year survival rate.
• SCLC incidence is 4.7 per 100,000, with 95% of cases associated with tobacco use.
• Patients often present with respiratory symptoms or asymptomatic metastases, with diagnosis confirmed via biopsy.

Purpose of the Study:

• To summarize the current understanding of SCLC incidence, risk factors, clinical presentation, staging, and treatment landscape.
• To highlight recent advancements in first-line and second-line therapies for both limited-stage (LS-SCLC) and extensive-stage (ES-SCLC).

Main Methods:

• Review of current literature and clinical data on SCLC.
• Analysis of treatment outcomes, including survival rates and response to various therapeutic regimens.
• Classification of SCLC into limited-stage (LS-SCLC) and extensive-stage (ES-SCLC) for treatment stratification.

Main Results:

• LS-SCLC shows improved survival with surgery or chemoradiotherapy plus immunotherapy (median survival up to 55.9 months with durvalumab).
• First-line treatment for ES-SCLC involves platinum-etoposide chemotherapy with PD-L1 inhibitors (durvalumab/atezolizumab), achieving 60-70% tumor shrinkage but median survival of 12-13 months.
• Second-line options for ES-SCLC include lurbinectedin and tarlatamab, offering modest response rates and progression-free survival.

Conclusions:

• SCLC remains a significant health challenge, particularly in its advanced stages.
• Combination chemotherapy and immunotherapy represent the current standard of care for both LS-SCLC and ES-SCLC.
• Emerging therapies like lurbinectedin and tarlatamab offer new avenues for relapsed/refractory ES-SCLC.